[Mycobacterium avium complex infections: the point on the treatments]

Related Experiment Video

Updated: Oct 23, 2026

Preparation of Agar Bead Embedded Mycobacterium abscessus to Inoculate Immunocompetent Mice Intratracheally
05:40

Preparation of Agar Bead Embedded Mycobacterium abscessus to Inoculate Immunocompetent Mice Intratracheally

Published on: April 25, 2025

S Brandissou1, B Hamel, B Veillet

  • 1Laboratoire de Pharmacocinétique, CHU Carémeau, Nimes, France.

Therapie
|January 1, 1997
PubMed

Insights

Clarithromycin monotherapy is effective for Mycobacterium avium complex (MAC) infections in AIDS patients. Combination therapy with clarithromycin, ethambutol, and rifabutin shows promising bacteriologic and clinical effects.

Area of Science:

  • Infectious Diseases
  • Immunology
  • Pharmacology

Background:

  • Mycobacterium avium complex (MAC) infections are common opportunistic infections in individuals with Acquired Immunodeficiency Syndrome (AIDS).
  • Advancements in antiretroviral therapy have increased survival rates for AIDS patients, leading to a rise in MAC infections among this population.
  • Limited controlled studies exist on the efficacy of various antibiotic treatments for MAC infections.

Purpose of the Study:

  • To evaluate the effectiveness of different antibiotic treatments for Mycobacterium avium complex (MAC) infections.
  • To identify the most effective monotherapy and combination therapy regimens for managing MAC infections in AIDS patients.

Main Methods:

  • Review of controlled assays evaluating antibiotic efficacy for MAC infections.
  • Comparison of monotherapy treatments including clarithromycin, azithromycin, clofazimine, rifampin, and liposomal encapsulated gentamicin.
  • Assessment of a specific poly(or combination) therapy regimen: clarithromycin, ethambutol, and rifabutin.

Main Results:

  • Clarithromycin, administered as one gram twice daily, demonstrated the highest efficacy in monotherapy.
  • The effectiveness of azithromycin, clofazimine, rifampin, and liposomal encapsulated gentamicin as monotherapies was not conclusively proven.
  • A combination therapy of clarithromycin (1 g twice daily), ethambutol (15 mg/kg/day), and rifabutin (600 mg/day) exhibited significant bacteriologic and clinical benefits.

Conclusions:

  • Clarithromycin is the most effective single-agent antibiotic for treating MAC infections in AIDS patients.
  • Combination therapy involving clarithromycin, ethambutol, and rifabutin is a highly effective treatment strategy for MAC infections, supported by its bacteriologic and clinical outcomes.

More Related Videos

Intradermal Inoculation of Mycobacterium avium in the Mouse Ear09:20

Intradermal Inoculation of Mycobacterium avium in the Mouse Ear

Published on: July 3, 2025

Identification of Mycobacterium Species by DNA Microarray Chip Method06:27

Identification of Mycobacterium Species by DNA Microarray Chip Method

Published on: June 24, 2025

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...